Results 161 to 170 of about 69,629 (300)

Framework for Approaching Patients with Suboptimal Deep Brain Stimulation Therapy Response despite Stimulation Optimization

Movement Disorders Clinical Practice, EarlyView.
Pratik Talati, Meredith Spindler, Casey H. Halpern   +2 more
wiley   +1 more source

Levodopa: A novel therapeutic prospect for liver disease. [PDF]

World J Hepatol
Xu J, Qian Y, Wang JM, Wu XL, Zheng YY.
europepmc   +1 more source

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers

Movement Disorders, EarlyView.
Abstract Background GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease.
Julian Agin‐Liebes, Alexander Haimovich, Rachel Griep, Nathan Galen Hatcher, Lihang Yao, Cheryl Waters, Shalini Padmanabhan, Roy N. Alcalay   +7 more
wiley   +1 more source

Outcome of People with Parkinson's Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa. [PDF]

Brain Sci
Santos García D, Legarda I, González Fernández TM, Rodríguez Sanz A, Morales-Casado MI, Peral A, Caballol N, Álvarez Sauco M, Campos Rodríguez I, Alonso Modino D, López Manzanares L, Olivares Romero J, Blanco Ollero A.   +12 more
europepmc   +1 more source

Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease is mainly characterized by dopaminergic neurodegeneration in the substantia nigra pars compacta (SNc) and α‐synuclein accumulation. The locus coeruleus (LC) is also affected in Parkinson's disease and linked to some nonmotor symptoms, but the extent and timing of its degeneration remain unclear.
Megan Carrillo, Nagore Hernández‐Pinedo, Josefa Zaldivar‐Diez, Isabel Pérez‐Santos, José A. Obeso, Carmen Cavada, Javier Blesa   +6 more
wiley   +1 more source

Therapeutic Spectrum of Intermittent Apomorphine in Parkinson's Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses. [PDF]

Noro Psikiyatr Ars
Ünal ED.
europepmc   +1 more source

Pickleball Tremor

Movement Disorders Clinical Practice, EarlyView.
Joseph Jankovic
wiley   +1 more source

Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Acute ischemic stroke (AIS) in those with Parkinson's disease (PD) is a growing healthcare burden but mortality studies are significantly lacking. Objective To map short‐ and long‐term survival, stratified by relevant comorbidities and stroke characteristics.
Lee E. Neilson, Chen Lin, Anusha Mishra, Gregory D. Scott   +3 more
wiley   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source

Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis. [PDF]

Eur J Neurol
Burton M, Marsden D, Harish D, Morris P, Heneghan C, Butler A, Nunan D.   +6 more
europepmc   +1 more source